| Ytd | -10.92% | |
| 1y | -67.19% |
| Open | 1.47 | Prev Close | 1.47 | Low | 1.47 | High | 1.47 | Mkt Cap | 9.05M |
| Vol | 6.26K | Avg Vol | 125.64K | EPS | -1.62 | P/E | -0.91 | Forward P/E | -41.25 |
| Beta | 0.64 | Short Ratio | 1.15 | Inst. Own | 27.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-25 | 50-d Avg | 1.75 | 200-d Avg | 2.01 | 1yr Est | 8.00 |
CMMB News
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'
Chemomab Therapeutics (NASDAQ:CMMB) ("Chemomab") and Scipher Medicine Corporation ("Scip
Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medi
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disea
2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance alon
TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo
Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ: CMMB - Get Free Report) saw a significant growth i
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifyin
TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment
Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring c
PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.
MQ, GES, TRV, CMMB and PARR have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 23, 2025.
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo
Juba, South Sudan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is launch
— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Execu
SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-i
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Pr
—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclero
— Reported Positive 48-Week Data from SPRING Trial — Nebokitug Treatment in PSC P atients with M ode
SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday afte
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% o
On Tuesday, 838 companies hit new 52-week lows.
Monday saw 825 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.